Acute Myeloid Leukemia, AML

Acute Myeloid Leukemia (AML) Research Reagents

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by clonal expansion of myeloid progenitors in bone marrow. The 2022 WHO and ICC classifications integrate morphology, immunophenotype, cytogenetics, and molecular genetics (NPM1, CEBPA, FLT3, IDH1/2, TP53, RUNX1) for definitive diagnosis and risk stratification. Targeted therapies have transformed AML treatment — midostaurin/gilteritinib for FLT3-mutant, ivosidenib/enasidenib for IDH1/2-mutant, venetoclax combinations for unfit patients, and gemtuzumab ozogamicin (anti-CD33 ADC) for favorable-risk disease.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Acute Myeloid Leukemia Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets in AML. FLT3 signaling, IDH1/2 metabolic reprogramming, and surface antigen targets for immunotherapy. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key AML research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

FLT3 (CD135) — FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations occur in approximately 30% and 7% of AML respectively, conferring adverse prognosis and sensitivity to FLT3 inhibitors (midostaurin, gilteritinib). Anti-FLT3 antibodies enable flow cytometric surface expression analysis, mutation-driven signaling studies, and FLT3-ligand binding characterization.
→ Browse FLT3 antibodies & proteins

IDH1 / IDH2 — IDH1 and IDH2 mutations occur in approximately 20% of AML, producing the oncometabolite D-2-hydroxyglutarate (2-HG) that drives epigenetic dysregulation. Anti-IDH1 R132H mutation-specific antibodies enable IHC screening, and pan-IDH antibodies support expression studies and ivosidenib/enasidenib response monitoring research.
→ Browse IDH1/IDH2 antibodies & proteins

CD33 (Siglec-3) — CD33 is a myeloid lineage marker expressed on the majority of AML blasts and the target for gemtuzumab ozogamicin (anti-CD33 ADC). Anti-CD33 antibodies are essential for flow cytometric immunophenotyping, MRD monitoring, ADC internalization studies, and CD33-targeted bispecific antibody/CAR-T therapeutic research.
→ Browse CD33 antibodies & proteins

CD123 (IL-3Rα) — CD123 is overexpressed on AML blasts and leukemic stem cells compared to normal hematopoietic stem cells, making it an attractive therapeutic target. Anti-CD123 antibodies support flow cytometric LSC identification, MRD analysis, and emerging CD123-targeted bispecific antibody and DART therapeutic development research.
→ Browse CD123 antibodies & proteins

References

1. Stone RM, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464. DOI

2. DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629. DOI

3. DiNardo CD, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386-2398. DOI

4. Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221. DOI

5. Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations. Blood. 2022;140(12):1345-1377. DOI

Recombinant Proteins

Antibodies

Assay Kits

Acute Myeloid Leukemia, AML

Acute Myeloid Leukemia (AML) Research Reagents

Get a free quote

Quick access

Contact Us